Cargando…

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajasekaran, Arun, Ngo, Thuy-Trang, Abdelrahim, Maen, Glass, William, Podoll, Amber, Verstovsek, Srdan, Abudayyeh, Ala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521341/
https://www.ncbi.nlm.nih.gov/pubmed/26232031
http://dx.doi.org/10.1186/s12882-015-0121-6
_version_ 1782383799267491840
author Rajasekaran, Arun
Ngo, Thuy-Trang
Abdelrahim, Maen
Glass, William
Podoll, Amber
Verstovsek, Srdan
Abudayyeh, Ala
author_facet Rajasekaran, Arun
Ngo, Thuy-Trang
Abdelrahim, Maen
Glass, William
Podoll, Amber
Verstovsek, Srdan
Abudayyeh, Ala
author_sort Rajasekaran, Arun
collection PubMed
description BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in the late stages of the disease. CASE PRESENTATION: We present the first case described in the medical literature of a patient with early renal glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling, acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the patient’s kidney functionality to the levels seen on initial presentation at our hospital. CONCLUSION: Large studies with long follow-up durations are necessary to identify and categorize the risk factors for the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether aggressive management of the myelofibrosis slows the progression of kidney disease.
format Online
Article
Text
id pubmed-4521341
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45213412015-08-01 Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib Rajasekaran, Arun Ngo, Thuy-Trang Abdelrahim, Maen Glass, William Podoll, Amber Verstovsek, Srdan Abudayyeh, Ala BMC Nephrol Case Report BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in the late stages of the disease. CASE PRESENTATION: We present the first case described in the medical literature of a patient with early renal glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling, acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the patient’s kidney functionality to the levels seen on initial presentation at our hospital. CONCLUSION: Large studies with long follow-up durations are necessary to identify and categorize the risk factors for the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether aggressive management of the myelofibrosis slows the progression of kidney disease. BioMed Central 2015-08-01 /pmc/articles/PMC4521341/ /pubmed/26232031 http://dx.doi.org/10.1186/s12882-015-0121-6 Text en © Rajasekaran et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Rajasekaran, Arun
Ngo, Thuy-Trang
Abdelrahim, Maen
Glass, William
Podoll, Amber
Verstovsek, Srdan
Abudayyeh, Ala
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title_full Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title_fullStr Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title_full_unstemmed Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title_short Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
title_sort primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521341/
https://www.ncbi.nlm.nih.gov/pubmed/26232031
http://dx.doi.org/10.1186/s12882-015-0121-6
work_keys_str_mv AT rajasekaranarun primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT ngothuytrang primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT abdelrahimmaen primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT glasswilliam primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT podollamber primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT verstovseksrdan primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib
AT abudayyehala primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib